Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CannaPharmaRx Inc CPMD

Healthcare Cannabis
CannaPharmaRX Inc. is a Canada-based cannabis company focused on producing customizable medical cannabis and craft products. The Company operates from its facility in Cremona, AB, Canada, and is able to produce over 6,000 kgs per year. The Company is focused on evaluation, negotiation, acquisition, and development cannabis cultivation projects in Canada. The Company's products include unique... see more

Recent & Breaking News (OTCPK:CPMD)

CannaPharmaRx Releases Year-in-Review Letter to Shareholders and Discusses Revenue Opportunities for 2023

Accesswire January 30, 2023

CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected

Accesswire January 11, 2023

Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond

Newsfile December 22, 2022

CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Revenue Over $30 Million

GlobeNewswire December 21, 2022

CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million

Accesswire December 21, 2022

CannaPharmaRx Secures New Strains for Declaration to be Incorporated Into Product Portfolio

Accesswire December 19, 2022

CannaPharmaRx Files Response with Health Canada in Preparation for Cremona Facility Opening

Accesswire September 7, 2022

CannaPharmaRx Signs Collaboration and Offtake Agreement with Spring Medical Group for Up to $12 Million of Commercial Cannabis

Accesswire August 24, 2022

CannaPharmaRx Enters into a Genetics Transfer Agreement with High Profile Cannabis Corp.

Accesswire June 29, 2022

CannaPharmaRx Acquiring Oklahoma Cannabis Facility

Accesswire February 10, 2022

CannaPharmaRx Stops Issuing Shares Under Previously Effective S-1

Accesswire February 8, 2022

CannaPharmaRx Enters into an Agreement for Supply of Genetics and Feed Stock to Accelerate Time to Market

Accesswire January 25, 2022

CannaPharmaRx Hires Key Personnel to Accelerate Output and Speed to Market for Cannabis Product

Accesswire January 19, 2022

CannaPharmaRx Completes Long Term Lease for Cremona Production Facility Which Should Yield 6,000Kg ($30,000,000)/Year

Accesswire January 6, 2022

CannaPharmaRX, Inc. Closes Sale of Hanover Facility for $2,000,000 CAD

Accesswire July 13, 2021

CannaPharmaRx Comments on Stock Promotion Flag

Accesswire June 24, 2021

CannaPharmaRX, Inc. Signs Agreement with Israeli Group K&K Consulting

Accesswire June 16, 2021

Cannabis market size to be worth USD$97.35 billion by 2026

Stockhouse Editorial June 9, 2021

CannaPharmaRX, Inc. Sells Hanover Facility for $2,000,000 CAD

Accesswire June 8, 2021

CannapharmaRx, Inc. Announces Changes to its Board of Directors

Accesswire March 25, 2021